RecruitingHyperphosphatemiaChronic Kidney Disease Requiring Chronic DialysisEnd Stage Renal Disease on Dialysis
A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia
Eligible age
18+ yrs
Accepts
All genders
Locations
15 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study is being conducted to characterize the safety, tolerability, and efficacy of AP306 at fixed doses in adults with hyperphosphatemia receiving maintenance hemodialysis.
Sponsor: R1 Therapeutics
Where it's recruiting
Alabama
Huntsville
California
Chula Vista · Los Angeles · San Dimas
Colorado
Denver
Connecticut
Middlebury · Orange
Florida
Fort Myers
Georgia
Dalton
Michigan
Shelby
Minnesota
Edina
Missouri
Kansas City
Nevada
Las Vegas
New Mexico
Albuquerque
New York
Ridgewood
Source: ClinicalTrials.gov · NCT06712654 · last updated 2026-08-03